Industry Says FDA Should Broaden Scope Of Pre-Submission Program
This article was originally published in The Gray Sheet
Executive Summary
FDA should allow pre-submission meetings to occur earlier in a device’s development cycle than what is stated in the recent draft guidance, industry groups say. The agency should also agree to review prior data as part of these meetings.
You may also be interested in...
Regulatory Briefs: Pre-Submission Program Final Guidance; FDA Meetings; HHS Health IT Nominations
FDA issues final guidance on its pre-submission program. The agency announced upcoming Gastroenterology and Urology Devices advisory panel meetings and a workshop for its Medical Device Epidemiology Network. More regulatory news.
Regulatory News In Brief
CDRH official says final guidance on pre-submission meetings will be issued this spring. FDA issues final guidance on retinal prostheses studies. More regulatory news.
FDA To Re-Issue Draft Guidance On Investigational Device Exemption Standards
The device center is responding to a provision in the FDA Safety and Innovation Act, passed last summer, which explicitly prohibits FDA from disapproving an IDE solely because the agency does not believe the study could support approval or clearance.